Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Gavilá, JoaquínOliveira, MafaldaPascual, TomásPerez-Garcia, JoseGonzàlez, XavierCanes, JordiParé, LaiaCalvo, IsabelCiruelos, EvaMuñoz, MontserratVirizuela, Juan ARuiz, IsabelAndrés, RaquelPerelló, AntoniaMartínez, JerónimoMorales, SerafínMarín-Aguilera, MercedesMartínez, DéboraQuero, Juan CLlombart-Cussac, AntonioPrat, Aleix2023-01-252023-01-252019-01-09http://hdl.handle.net/10668/13391enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Breast cancerHER2HER2-enrichedPAM50cardiac safetyintrinsic subtypesneoadjuvantAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCardiotoxicityChemotherapy, AdjuvantDoxorubicinFemaleHumansMiddle AgedNeoadjuvant TherapyPaclitaxelPolyethylene GlycolsReceptor, ErbB-2TrastuzumabSafety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.research article30621698open access10.1186/s12916-018-1233-11741-7015PMC6325829https://doi.org/10.1186/s12916-018-1233-1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325829/pdf